Delivering Life-changing Value as a Global Specialty Pharma

J.P. Morgan Healthcare Conference
January 10, 2022

Masashi Miyamoto, Ph.D.
Representative Director of the Board, President and Chief Executive Officer
This document contains certain forward-looking statements relating to such items as the Company’s forecasts, targets and plans (including those of its domestic and overseas subsidiaries). These forward-looking statements are based upon information available to the Company at the present time and upon reasonable assumptions made by the Company in making its forecasts, but actual results may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, inherent risks in the business activities of the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of product side effects, legal regulation risks, product defect risks, risks of changes to prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

This document is provided to investors for informational purposes only. It contains information on pharmaceutical products (including products under development), but the contents should not be construed as promotion, advertising or as a medical recommendation.

The registered trademarks contained herein are the property of Kyowa Kirin Co., Ltd. or respective owners.
Agenda

4 Who We Are
12 Global Strategic Products Driving Our Growth
18 Next-generation Strategic Products
30 Outlook for the Future
Who We Are
Vision

Our New Vision toward 2030

Kyowa Kirin will realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based Global Specialty Pharmaceutical company built on the diverse team of experts with shared passion for innovation.

Provide pharmaceuticals for unmet medical needs

Address patient-centric healthcare needs

Retain the trust of society
Overview

Kyowa Kirin

Global

5,423 Valuable employees worldwide

¥318.4 billion Annual consolidated revenue in 2020

Specialty Pharma

39 countries/regions
Extensive market reach, with a presence worldwide

48% Overseas revenue ratio in 2020

152% Sales growth for the three global strategic products (vs. 2019)

Over 50 Pharmaceutical products on the market including 4 monoclonal antibodies

39 countries/regions
Extensive market reach, with a presence worldwide

48% Overseas revenue ratio in 2020

152% Sales growth for the three global strategic products (vs. 2019)

Over 50 Pharmaceutical products on the market including 4 monoclonal antibodies

Strengths in
4 Therapeutic fields

Nephrology
Oncology
Immunology/Allergy
Central Nervous System

As of Dec 31, 2020
Global Network

Sales Breakdown by Customer Region (FY2020)
- Asia: 9.7%
- Europe: 15.2%
- Americas: 22.7%
- Japan: 52.3%
- Overseas Revenue: 48%

As of Dec 31, 2020

Japan: 4 companies
North America: 6 companies
Asia and Oceania: 8 companies
EMEA: 20 companies
History

1907  Kirin Brewery founded

1949  Kyowa Hakko Kogyo founded

1951  Pharma business launched as the first in Japan to mass-produce Streptomycin (a tuberculosis drug)

1984  A joint venture Kirin-Amgen founded with Amgen

1990  ESPO® launched

1997  Research leading to Crysvita began

2008  Human antibody producing technology established

2018  Kyowa Hakko Kirin (now Kyowa Kirin) founded

2018  Crysvita launched (EU & US)

2019  Nourianz launched (US)

2020  Poteligeo launched (EU)

2020  Poteligeo launched (US)
Key Marketed Products

**Nephrology**
- **NESP**<sup>®</sup>
  - Erythropoiesis Stimulating Agent
  - Japan and Asia
- **REGPARA**
  - Calcium receptor agonist
  - Japan and Asia
- **オルケディア**
  - Calcium receptor agonist
  - Japan
- **オングリザ**
  - DPP-4 inhibitor
  - Japan

**Oncology**
- **POTELIGEO**<sup>®</sup>
  - Anti-CCR4 mAb
  - Japan, US and EU
- **Abstral**
  - Sublingual fentanyl
  - Japan and EU
- **ジーラスダ**
  - Long-lasting G-CSF/G-CSF
  - Japan and Asia<sup>1</sup>
- **リツキシマブ BS**
  - Rituximab biosimilar
  - Japan

**Immunology/Allergy**
- **Allelock**<sup>®</sup>
  - Anti-allergic agent
  - Japan and Asia
- **NOURIANZ**
  - Adenosine A<sub>2a</sub>R antagonist
  - Japan and US
- **パタノール**
  - Ophthalmic Anti-allergic agent
  - Japan
- **ルミセフ**
  - Anti-IL17R mAb
  - Japan
- **ドボベット**
  - Vitamin D3/Corticosteroid
  - Japan

**Central Nervous System**
- **デパケン**<sup>®</sup>
  - Antiepileptic agent
  - Japan
- **トピナ**
  - Antiepileptic agent
  - Japan
- **Coniel**
  - Calcium channel blocker
  - Japan and Asia

**Others**
- **Anti-FGF23 mAb**
  - Japan, US<sup>2</sup> and EU
- **Rituximab biosimilar**
  - Japan, US and EU
- **Sublingual fentanyl**
  - Japan and EU

*1 Pegfilgrastim only available in Japan, *2 Marketed by Ultragenyx Pharmaceutical Inc.
Proprietary Technologies for Life-changing Value Creation

**POTELLIGENT® Technology**

An ADCC-enhancing technology that realizes effective target cell elimination by antibody afucosylation.

- Antibody-dependent cellular cytotoxicity (ADCC)
- NK cell
- Target cell
- FcγRIIIa

1. Sugar chains are in the tail of antibodies called Fc portion.
2. They contain fucose, a kind of sugar.
3. The removal of fucose allows increased antibody-dependent cellular cytotoxicity (ADCC) activity.

**Human Antibody Producing Technology**

A technology that enables to generate fully human antibodies with the same diversity as natural antibodies using chromosome engineering.

**KHK4083/AMG 451**

Potelligent® (low/no fucose) vs. Conventional (highly fucosylated) ADCC activity (%) vs. Antibody concentration (µg/mL).
Next-Generation Technologies for Life-Changing Value Creation

Bispecific Antibody Technology

- Selection of linkers derived from Immunoglobulin (Ig) and the common sequence of L Chains
- Versatility equivalent to wild type IgG
- Unique biology based on bivalent x bivalent binding

Drug Discovery Collaborations

- Revolutionary small molecule drug discovery (with Axcelead)
- Data-driven drug discovery (with InveniAI)
- RNA structure-targeted drug discovery (with xFOREST and Axcelead)
Global Strategic Products Driving Our Growth
Strong Growth of Global 3 Brands (G3B)

**Crysvita**
(Burosumab, an anti-FGF23 fully human monoclonal antibody)
- X-linked hypophosphatemia (XLH)
- Tumor-induced osteomalacia (TIO)

**Poteligeo**
(Mogamulizumab, an anti-CCR4 humanized antibody)
- Mycosis fungoides (MF)
- Sézary syndrome (SS)

**Nouriast/Nourianz**
(Istradefylline, an Adenosine A2A receptor antagonist)
- Parkinson’s disease (PD) experiencing “off” episodes

---

**Sales revenue (billions of yen)**

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021 (Plan)</th>
<th>2025 (Plan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>21.0</td>
<td>55.1</td>
<td>83.8</td>
<td>117.8</td>
<td></td>
</tr>
<tr>
<td>Sales from G3B</td>
<td>271.5</td>
<td>305.8</td>
<td>318.4</td>
<td>351.0</td>
<td></td>
</tr>
</tbody>
</table>

Driven by G3B
Crysvita

Burosumab, an anti-FGF23 fully human monoclonal antibody

- **2000**: Cloning of FGF23 cDNA
- **2013**: Identify FGF23 Function
- **2018**: Collaborate with Ultragenyx
- **2019**: Launch in EU (adults)
- **2020**: Launch in Japan
- **2023**: To initiate own sales in US

**Indications**

- **US**: XLH, TIO
- **EU**: XLH
- **JP**: XLH (TIO), FGF23-related hypophosphatemic rickets and osteomalacia

**Annual sales growth**

<table>
<thead>
<tr>
<th>Year</th>
<th>NA+EMEA+JP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>7.7</td>
</tr>
<tr>
<td>2019</td>
<td>32.6</td>
</tr>
<tr>
<td>2020</td>
<td>58.2</td>
</tr>
<tr>
<td>2021</td>
<td>82.7 [Bn JPY]</td>
</tr>
</tbody>
</table>

**Number of patients**

<table>
<thead>
<tr>
<th>Year</th>
<th>US</th>
<th>EU</th>
<th>JP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>700</td>
<td>2000</td>
<td>700</td>
</tr>
<tr>
<td>2020</td>
<td>3000</td>
<td>3000</td>
<td>3000</td>
</tr>
</tbody>
</table>

*1 Marketed by Ultragenyx Pharmaceutical Inc.; *2 Excl. patients under Early Access Program and patients who have not started the reimbursement process
Crysvita

Global Evidence Generation Project

Europe
XLH Registry

Asia
SUNFLOWER

Americas
DMP*

Medical Insights
Generating Real World Evidence

*B: Disease Monitoring Program

https://xlhlink.eu/
**Poteligeo**

Mogamulizumab, an anti-CCR4 humanized antibody

- **2012**: Establish POTTELIGENT® technology
- **2018**: Launch in Japan
- **2020**: Launch in US
- **2020**: Launch in EU

- **The first glyco-engineered antibody to reach the market**
- **Indications**

<table>
<thead>
<tr>
<th>Year</th>
<th>US</th>
<th>EU</th>
<th>JP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>MF</td>
<td>MF</td>
<td>ATL PTCL CTCL</td>
</tr>
<tr>
<td>2019</td>
<td>MF</td>
<td>MF</td>
<td>ATL PTCL CTCL</td>
</tr>
<tr>
<td>2020</td>
<td>MF</td>
<td>MF</td>
<td>ATL PTCL CTCL</td>
</tr>
<tr>
<td>2021</td>
<td>MF</td>
<td>MF</td>
<td>ATL PTCL CTCL</td>
</tr>
</tbody>
</table>

ATL: adult T-cell leukemia/lymphoma; PTCL: peripheral T-cell lymphoma; CTCL: cutaneous T-cell lymphoma

**Annual sales growth* (NA+EMEA+JP)**

<table>
<thead>
<tr>
<th>Year</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>3.9</td>
</tr>
<tr>
<td>2019</td>
<td>12.8</td>
</tr>
<tr>
<td>2020</td>
<td>13.6</td>
</tr>
<tr>
<td>2021</td>
<td>19.3 [Bn JPY]</td>
</tr>
</tbody>
</table>

* Excl. patients under Early Access Program and patients who have not started the reimbursement process
**Nourianz/Nouriast**

Istradefylline, an Adenosine $A_{2A}$ receptor antagonist

- **1994**: Discovery of Istradefylline
- **2013**: Launch in Japan
- **2019**: Launch in US
- **2026**: Next generation $A_{2A}$R antagonist KW-6356 to be launched

**Indications**

- MOA (Simple illustration)
  - Levodopa replaces lost dopamine, like pressing down on the gas
  - Istradefylline blocks $A_{2A}$ receptors, like lifting the brake

- US / JP
  - PD experiencing “off” episodes

**Annual sales growth (NA+JP)**

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021 (Plan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sales</td>
<td>9.4</td>
<td>9.8</td>
<td>12.0</td>
<td>15.8</td>
</tr>
</tbody>
</table>

[1 Bn JPY = ¥1 trillion]
Next-generation Strategic Products
# Next-generation Strategic Products

<table>
<thead>
<tr>
<th>Country / region*1</th>
<th>Indication*2</th>
<th>Approval year*3</th>
<th>Total addressable market*4</th>
<th>No. of patients*5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KHK4083/AMG 451</strong></td>
<td>NA/EU/JP</td>
<td>Atopic dermatitis</td>
<td>2025/2026</td>
<td>★★★</td>
</tr>
<tr>
<td><strong>KW-6356</strong></td>
<td>NA/EU/JP</td>
<td>Parkinson’s disease</td>
<td>2025</td>
<td>★★★</td>
</tr>
<tr>
<td><strong>ME-401 Zandelisib</strong></td>
<td>NA/EU/JP</td>
<td>Follicular lymphoma</td>
<td>2023</td>
<td>★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marginal zone lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RTA 402 Bardoxolone methyl</strong></td>
<td>JP/Asia</td>
<td>Alport syndrome</td>
<td>2022</td>
<td>★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diabetic kidney disease (DKD)</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autosomal dominant polycystic kidney disease (ADPKD)</td>
<td>2025</td>
<td></td>
</tr>
<tr>
<td><strong>KHK7791 Tenapanor</strong></td>
<td>JP</td>
<td>Hyperphosphatemia under maintenance dialysis</td>
<td>2023</td>
<td>★☆☆</td>
</tr>
</tbody>
</table>

*1 Countries or regions where Kyowa Kirin currently has marketing rights and will launch products (or will conduct marketing activities); products may not be launched in all countries or regions shown in the table.

*2 Expected indications as of the date of this document; indications may ultimately differ to expectations due to status of approvals from regulatory authorities.

*3 Expected year of first approval

*4 Expected total addressable market, which is the sum of all products for the indications shown in *2, in all countries or regions defined in *1, not projected sales or the Company’s targets.

*5 Total number of estimated patients in all countries or regions defined in *1.

*6 The size of the total addressable market and patient numbers are based on our estimates.
KHK4083/AMG 451 targets OX40 as a potential novel target for AD treatment

- Activation of Th2 and other T-cell subsets is central in atopic dermatitis (AD)
- The OX40–OX40L axis plays a critical role in long-lasting T-cell responses
  - OX40 is expressed by activated T cells after antigen recognition and binds OX40L on APCs, facilitating the effector function of T cells
- KHK4083/AMG 451 is a fully human, anti-OX40, non-fucosylated IgG1 mAb with enhanced ADCC\(^1\) that acts by
  - Partially depleting activated T cells\(^2\)\(^1\)
  - Blocking T-cell clonal expansion and memory T-cell formation\(^2\)\(^2\)

AD, atopic dermatitis; ADCC, antibody-dependent cellular cytotoxicity; APC, antigen-presenting cell; CD28, cluster of differentiation 28; IgG, immunoglobulin G; MHC, major histocompatibility complex; mAb, monoclonal antibody; TCR, T-cell receptor; Th2, T-helper 2

KHK4083/AMG 451: Achieved Primary Endpoint in Phase 2 Study

### Phase 2 Study Design

**Screening**
- Adults with chronic AD
- Randomization (1:1:1:1:1)
- Location: US, Japan, Germany, and Canada

**Treatment A** (Up to Week 18)
- Placebo
- KHK4083 600 mg SC Q2W

**Treatment B** (Week 18-Week 36)
- KHK4083 150 mg SC Q4W
- KHK4083 300 mg SC Q2W
- KHK4083 600 mg SC Q2W
- KHK4083 600 mg SC Q4W

**Follow-up**
- W16 (Last dose in Treatment A)
- W34 (Last dose)
- W36 (End of Treatment)
- W56 (End of Study)

**Emollient** (twice daily)

### Primary Endpoint: % change from baseline in EASI score at W16 (LOCF, FAS)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n</th>
<th>LS mean % change (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4083 150 mg</td>
<td>52</td>
<td><strong>−48.33% (−62.62, −34.04)</strong>*</td>
</tr>
<tr>
<td>Q4W</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4083 300 mg</td>
<td>52</td>
<td><strong>−57.35% (−71.27, −43.43)</strong>*</td>
</tr>
<tr>
<td>Q2W</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4083 600 mg</td>
<td>54</td>
<td>−61.07% (−75.19, −46.96)</td>
</tr>
<tr>
<td>Q2W</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4083 600 mg</td>
<td>57</td>
<td><strong>−49.72% (−64.27, −35.17)</strong>*</td>
</tr>
<tr>
<td>Q4W</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td><strong>−15.01% (−28.60, −1.43)</strong></td>
</tr>
</tbody>
</table>

**EASI**, Eczema Area and Severity Index; LS, least square; Q2W, every 2 weeks; Q4W, every 4 weeks

**p<0.001 for difference versus placebo**
KHK4083/AMG 451: Durable EASI-75 Response Confirmed

Secondary Endpoint: EASI-75 Responder Proportion

<table>
<thead>
<tr>
<th>Treatment period A (Placebo-controlled period)</th>
<th>Treatment period B (All groups received KHK4083)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4083 150mg Q4W</td>
<td>KHK4083 150mg Q4W</td>
</tr>
<tr>
<td>KHK4083 600mg Q4W</td>
<td>KHK4083 600mg Q4W</td>
</tr>
<tr>
<td>KHK4083 300mg Q2W</td>
<td>KHK4083 300mg Q2W</td>
</tr>
<tr>
<td>KHK4083 600mg Q2W</td>
<td>KHK4083 600mg Q2W</td>
</tr>
<tr>
<td>Placebo/KHK4083 600mg Q2W</td>
<td>Placebo/KHK4083 600mg Q2W</td>
</tr>
</tbody>
</table>

EASI-75: EASI score of 75% or greater improvement from baseline
KHK4083/AMG 451: Collaboration with Amgen

Amgen makes a $400 million up-front payment to Kyowa Kirin and future contingent milestone payments potentially worth up to an additional $850 million, as well as royalty payments on future global sales.

<table>
<thead>
<tr>
<th></th>
<th>US</th>
<th>Europe and Asia (ex. JP)</th>
<th>JP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development</td>
<td>Amgen leads development</td>
<td>Amgen leads development</td>
<td>Kyowa Kirin leads development</td>
</tr>
<tr>
<td></td>
<td>Share development cost</td>
<td>Share development cost</td>
<td></td>
</tr>
<tr>
<td>Commercialization</td>
<td>Amgen commercializes and books sales</td>
<td>Amgen commercializes and books sales</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kyowa Kirin co-promotes and shares promotion cost</td>
<td>Kyowa Kirin has opt-in rights for co-promotion</td>
<td></td>
</tr>
<tr>
<td>Sales royalties</td>
<td>Double-digit royalty to Kyowa Kirin</td>
<td>Double-digit royalty to Kyowa Kirin</td>
<td></td>
</tr>
<tr>
<td>Commercial supply</td>
<td>Amgen supplies</td>
<td>Amgen supplies</td>
<td>Kyowa Kirin supplies</td>
</tr>
</tbody>
</table>
Zandelisib (ME-401): Clinical and Commercial Opportunity

>8,000 U.S. Patients With Relapsed/Refractory Follicular Lymphoma

$1B Addressable Market

Market Opportunity

- PI3Kδ inhibitors deliver potent efficacy, but utility limited by the extensive T-reg mediated toxicity
- R/R FL has several treatment options but no standard of care
- PI3Kδ inhibitors limited to modest ≥ 3rd Line FL use due to risk/benefit of current therapies

Zandelisib Opportunity

- Product attributes and novel treatment schedule could reset expectations of PI3Kδ inhibitors
- Compelling emerging profile supports best-in-class opportunity in 3L+ FL
- Unique zandelisib properties and combinability could expand utility to earlier lines of FL and into other BCMs

Global License, Development and Commercialization Agreement to Optimize Zandelisib Value (April 2020)

US: cost-sharing, co-promotion, MEI Pharma books sales
Ex-US: Kyowa Kirin has exclusive rights, escalating tiered sales royalty payments to MEI starting in teens

BCMs: B-cell malignancies
Zandelisib: Emerging Profile

**Phase 2 study (TIDAL) in patients with r/r FL**

<table>
<thead>
<tr>
<th><strong>Overall Response Rate (ORR)</strong></th>
<th>70.3%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>95% CI (59.8, 79.5)</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Complete Response Rate (CR)</strong></th>
<th>35.2%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>95% CI (25.4, 45.9)</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Duration of Response:**
Insufficiently mature to estimate final DOR: with median follow-up time for response of 8.4 months, median DOR had not been reached

**Zandelisib**

<table>
<thead>
<tr>
<th><strong>Cycles 1 and 2</strong></th>
<th><strong>Intermittent Dosing on Cycles ≥3</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily dosing 8 wks</td>
<td>Daily 1 wk No therapy 3 wks</td>
</tr>
</tbody>
</table>

**Discontinuation Rate Due to Any Drug Related Adverse Event**
9.9%

**Adverse Events of Special Interest (Grade ≥3)**
- 1.7% ALT/AST Elevation
- 1.7% Colitis
- 5.0% Diarrhea
- 2.5% Mucositis
- 0.8% Pneumonitis
- 3.3% Rash

**≤ 5% each**

**Median Follow-up of 9.4 Months (0.8-24)**

N=91 in the primary efficacy population for the evaluation of ORR and DOR.

Note: ORR assessed by IRC after a minimum follow-up of 6 months and represents the primary endpoint of the TIDAL study. Safety and duration of response data are as of the data cutoff date; the data cutoff date is approximately 6 months after the last patient in the primary efficacy population received their first dose of zandelisib. With exception of the ORR and CR data reported in the primary follicular lymphoma efficacy population of 91 patients, the data reported today provides an initial look at the data as of the data cutoff date and is interim and subject to change as more patient data become available. Because the data reported today is from an ongoing study, the final data may differ materially from the data reported in this presentation.
Zandelisib: Exploring Full Potential as Backbone Therapy

**Zandelisib Single Agent**
- Ph 2 Study TIDAL in 3L+ FL and MZL
- Ph 2 Study K02 in 3L+ in iNHL (Japan)

**Zandelisib + Rituximab**
- Ph 3 Study COASTAL in 2L+ FL and MZL

**Other Zandelisib Combinations**
- + Zanubrutinib in FL and MCL in 2L+
- + R-CHOP in DLBCL in 1L
- + Ven-R in CLL

Additional Studies in Active Planning and More Under Consideration

CLL: chronic lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; iNHL: indolent B-cell non-Hodgkin lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; R-CHOP: rituximab-cyclophosphamide/doxorubicin/prednisone/vincristine; Ven-R: venetoclax-rituximab
Bardoxolone Methyl (RTA 402): Clinical and Commercial Opportunity

- Potential to be the first drug to improve renal function
- Innovative drug is highly anticipated (No drug can improve renal function)
- Novel MOA - Nrf2 activation
- Priority Review Designation under Japanese SAKIGAKE system
- Potential to be the first drug to improve renal function

Market Opportunity

- Increasing diabetes patients in Japan
- DKD - the leading cause of incident dialysis (around 40%)
- Innovative drug is highly anticipated (No drug can improve renal function)

License Agreement on Bardoxolone Methyl for Japan and Certain Asian Markets (January 2010)

Kyowa Kirin has exclusive rights, sales royalty payments to Reata ranging from the low teens to the low 20%

*1 National Health and Nutrition Survey (2016), MHLW/Ministry of Health, Labour and Welfare; *2 CKD: chronic kidney disease
Bardoxolone Methyl: Increase GFR in CKD Patients with Type 2 Diabetes

Phase 2 study (TSUBAKI) in CKD patients with Type 2 Diabetes

Phase 3 study (AYAME) in DKD patients

# Expected News Flow in FY2022

<table>
<thead>
<tr>
<th>Code/Generic Name</th>
<th>Target Disease</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4083/AMG 451</td>
<td>Atopic dermatitis</td>
<td>P3 FPI</td>
</tr>
<tr>
<td>KW-6356</td>
<td>Parkinson’s disease</td>
<td>P2b detailed data; P3 FPI</td>
</tr>
<tr>
<td>ME-401 Zandelisib</td>
<td>FL/MZL (2L, R combo); iNHL (3L, mono); CLL (Ven-R combo)</td>
<td>Enrollment ongoing; P2 Topline data; P2 FPI</td>
</tr>
<tr>
<td>RTA 402 Bardoxolone methyl</td>
<td>Alport syndrome; Diabetic kidney disease</td>
<td>Regulatory decision (JP); P3 LPO</td>
</tr>
<tr>
<td>KHK7791 Tenapanor</td>
<td>Hyperphosphatemia under maintenance dialysis</td>
<td>Marketing application (JP)</td>
</tr>
</tbody>
</table>

FPI: first patient in; FL: follicular lymphoma; MZL: marginal zone lymphoma; iNHL: indolent B-cell non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; Ven-R: venetoclax-rituximab; LPO: last patient out

As of Nov 1, 2021
Outlook for the Future

- Delivering Life-changing Value as a GSP -
Outlook toward 2030

Maximize the Value of G3B

Accelerate Growth by Next-generation Global Products
- KHK4083
- KW-6356
- ME-401

Generate Sustained Growth and Achieve our New Vision for Kyowa Kirin

Expand Sales of Global Products to Drive Growth

Generate Revenue from Existing Products and the Launch of New Local Products
FY2021-2025 Medium Term Business Plan

Delivering Life-changing Value as a GSP

Strategy to Realize our New Vision

Financial Indexes
- ROE: 10% or higher
- Revenue growth ratio: CAGR 10% or higher
- R&D expense ratio: Targeting 18-20% to support active investment
- Core operating profit ratio: 25% or higher by 2025
- Dividend payout ratio: Targeting sustained dividend hikes with 40% (based on core EPS)

Address patient-centric healthcare needs
Provide pharmaceuticals for unmet medical needs
Retain the trust of society
Reinforce human resources and structures that support the creation of Life-changing value

Our New Vision toward 2030
To be in 2025
- Maximize the value of global products
- Establish framework to ensure stable global supplies
- Build a drug pipeline to drive growth beyond 2025
- Launch services that go beyond pharmaceuticals
- Foster a corporate culture suited to global business development

Delivering patient-centric healthcare needs
Providing pharmaceuticals for unmet medical needs
Retaining the trust of society
Reinforcing human resources and structures that support the creation of Life-changing value

Delivering Life-changing Value as a GSP
Appendix
Stock Information (As of December 31, 2020)

Stock Listing
Tokyo

Securities Code
4151

Transfer Agent of Common Stock
Sumitomo Mitsui Trust Bank, Limited
1-4-1, Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan
http://www.smtb.jp/personal/agency/index.html

Number of Shares of Common Stock
Authorized: 987,900,000
Issued: 540,000,000

Number of Shareholders
30,946

Shareholding by Type of Investor (Number)
- Individuals 6.73% (29,631)
- Overseas companies 15.10% (643)
- Securities companies 2.41% (58)
- Financial institutions 20.49% (82)
- Other companies 54.74% (531)
- Treasury stock 0.52% (1)

Principal Shareholders

<table>
<thead>
<tr>
<th>Number of Shares Held (Thousands)</th>
<th>Percentage of Total Shares Issued (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kirin Holdings Company, Limited</td>
<td>288,819</td>
</tr>
<tr>
<td>The Master Trust Bank of Japan, Ltd. (Trust account)</td>
<td>45,422</td>
</tr>
<tr>
<td>Custody Bank of Japan, Ltd. (Trust account)</td>
<td>23,827</td>
</tr>
<tr>
<td>State Street Bank &amp; Trust Company 505223</td>
<td>7,839</td>
</tr>
<tr>
<td>Custody Bank of Japan, Ltd. (Trust account 7)</td>
<td>5,527</td>
</tr>
<tr>
<td>Mizuho Trust &amp; Banking Co., Ltd. (Retirement Benefit Trust for Mizuho Bank, Ltd.)</td>
<td>4,539</td>
</tr>
<tr>
<td>State Street Bank West Client-Treasury 505234</td>
<td>4,337</td>
</tr>
<tr>
<td>SMBC Nikko Securities Inc.</td>
<td>3,812</td>
</tr>
<tr>
<td>JP Morgan Chase Bank 385781</td>
<td>3,651</td>
</tr>
<tr>
<td>State Street Bank &amp; Trust Company 505103</td>
<td>3,416</td>
</tr>
</tbody>
</table>

1. The 4,539 thousand shares held by Mizuho Trust & Banking Co., Ltd. (Retirement Benefit Trust for Mizuho Bank, Ltd.) are the trust assets entrusted by Mizuho Bank for its retirement benefit trust, and voting rights for the shares are retained by Mizuho Bank.
2. The 2,823 thousand shares held by the Company as treasury stock are excluded from the above because treasury stock has no voting rights.

Stock Price and Trading Volume

Stock Price (¥)

Trading Volume (Millions of shares)

Total Shareholder Return (TSR)

<table>
<thead>
<tr>
<th>Kyowa Kirin Co., Ltd.</th>
<th>Past 4 years</th>
<th>Past 3 years</th>
<th>Past 2 years</th>
<th>Past 1 year</th>
<th>Current year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>85.7%</td>
<td>116.5%</td>
<td>113.0%</td>
<td>141.1%</td>
<td>156.0%</td>
</tr>
<tr>
<td>TOPIX Total Return Index</td>
<td>100.0%</td>
<td>122.6%</td>
<td>103.0%</td>
<td>121.7%</td>
<td>130.7%</td>
</tr>
</tbody>
</table>